Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination

Table 3 Proportion of patients developing IgA antibodies against SARS-CoV-2 after infection and vaccination

	Infected		Vaccinated
	N	n (%)	n	n (%)	p-value
IgA antibody seroconversion rate against RBD
Overall	68	52 (76.5)	247	102 (41.3)	< 0.001
KTR	21	17 (80.9)	129	57 (44.2)	0.002
HD	24	18 (75.0)	85	38 (44.7)	0.009
Control	23	17 (73.9)	33	7 (21.2)	< 0.001
IgA antibody seroconversion rate against S1S2
Overall	68	60 (88.4)	247	122 (49.4)	< 0.001
KTR	21	19 (90.5)	129	57 (44.2)	< 0.001
HD	24	21 (87.5)	85	50 (58.8)	0.009
Control	23	20 (87.0)	33	15 (45.5)	0.002

Table showing seroconversion IgA antibodies directed to RBD and S1S2 of SARS-CoV-2. KTR Kidney transplant recipients, HD hemodialysis

ISSN: 1743-422X